Drug Profile
MK 1092
Alternative Names: MK-1092Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Merck Sharp & Dohme
- Class Antihyperglycaemics
- Mechanism of Action Prostaglandin D2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 1 diabetes mellitus
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus in USA (SC, Injection)
- 12 Jun 2020 Interim efficacy, adverse events and pharmacokinetics data from a phase I trial in Diabetes mellitus presented at the American Diabetes Association (ADA-2020)
- 08 Nov 2018 Merck Sharp & Dohme completes a phase I trial in healthy volunteers in USA (NCT03170544)